Combs Andrew
SEC insider (Form 3/4/5 filer). CIK 0001825005. Chief Chemistry Officer at Prelude Therapeutics Inc (PRLD). 5 reported Form 4/5 transactions since Sep 2024; latest on Feb 4, 2026. Located in WILMINGTON, DE.
Companies Combs Andrew has filed insider reports for
- Prelude Therapeutics Inc (PRLD): Officer, Chief Chemistry Officer
Combs Andrew
CIK: 0001825005
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Prelude Therapeutics Inc
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Feb 4, 2026PRLD
Prelude Therapeutics Inc
AwardDirectEmployee Stock Option (right to buy)
230K shares- - Mar 25, 2025PRLD
Prelude Therapeutics Inc
PurchaseDirect100K shares at avg. $0.69$69K - Feb 4, 2025PRLD
Prelude Therapeutics Inc
AwardDirectEmployee Stock Option (right to buy)
175K shares- - Dec 23, 2024PRLD
Prelude Therapeutics Inc
PurchaseDirect60K shares at avg. $1.37$82K - Dec 20, 2024PRLD
Prelude Therapeutics Inc
PurchaseDirect3.1K shares at avg. $1.15$4K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 4, 2026 | PRLD Prelude Therapeutics Inc | Award Employee Stock Option (right to buy) | 230,000 | - | - | Direct |
| Mar 25, 2025 | PRLD Prelude Therapeutics Inc | Purchase | 100,000 | $0.69 | $69,250 | Direct |
| Feb 4, 2025 | PRLD Prelude Therapeutics Inc | Award Employee Stock Option (right to buy) | 175,000 | - | - | Direct |
| Dec 23, 2024 | PRLD Prelude Therapeutics Inc | Purchase | 60,000 | $1.37 | $82,002 | Direct |
| Dec 20, 2024 | PRLD Prelude Therapeutics Inc | Purchase | 3,075 | $1.15 | $3,536 | Direct |
1-5 of 5 transactions